News
This chart describes the different types of insulin and how they can affect you. Within each category, there are different formulations that may vary the onset, peak, or duration. Share on Pinterest ...
Continuous subcutaneous insulin infusion (CSII) has become an indispensable modality in the management of type 1 diabetes. This therapy employs an insulin pump to deliver both basal and bolus ...
The price of insulin has tripled in the past 10 years, and people with diabetes across the US are struggling to afford the drug that keeps them alive. Business Insider Subscribe Newsletters ...
Several short-term and long-term clinical trials have shown that the addition of pramlintide to preexisting insulin therapy improved postprandial and overall glycemic control (hemoglobin A 1c ...
This is where the dual pharmacy specialties — pharmacokinetics (PK) and pharmacodynamics (PD) — come into play. Pharmacokinetics studies how a drug is absorbed into the body over time — how it ...
This is where the dual pharmacy specialties — pharmacokinetics (PK) and pharmacodynamics (PD) — come into play. Pharmacokinetics studies how a drug is absorbed into the body over time — how it ...
Adocia, the biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides, announced today positive results from ...
Pre-administration of rHuPH20 prior to insulin infusion provides consistent ultrafast absorption and superior post-meal glucose control SAN DIEGO, Oct. 27, 2011 -- /PRNewswire/ -- Halozyme | Pre ...
--MannKind Corporation announced today that the Afrezza ® safety and pharmacokinetics study in pediatric patients is now enrolling children 4-7 years of age and nearing completion for Cohort 2..
U-500 regular insulin has a pharmacokinetic and pharmacodynamic profile that differs from U-100 human ... and medication bags and the front of the patient's hospital chart at the nursing ...
In addition, the Stanford team used a pharmacokinetics model to predict the drugs’ performance in humans. The model shows a human UFAL time to onset of 2.5 minutes, peak exposure at 10 minutes ...
DANBURY, Conn., Nov. 12, 2010 /PRNewswire via COMTEX/ -- Scientists from Biodel Inc. (Nasdaq: BIOD) reported new findings from the company's Linjeta(TM), insulin glargine, "smart" basal insulin ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results